Introduction
============

Carbamazepine (CBZ), a commonly prescribed medication in psychiatry and neurology, produces side effects with an incidence ranging from 33%--50%. CBZ-induced hyponatremia is a well-described side effect, and numerous studies have shown that age, hyponatremia dosage/level, and polypharmacy are predisposing risk factors for CBZ-induced hyponatremia ([@b7-ijgm-1-21]). Polypharmacy is a particularly important risk factor ([@b13-ijgm-1-21]).

We report a case of the syndrome of inappropriate antidiuresis (SIAD) caused by interferon-alpha therapy in a patient with chronic hepatitis C virus infection, who had been treated with CBZ for a long time.

Case report
===========

Twelve days after the start of interferon-alpha and ribavirin therapy, a 31-year-old man was admitted for investigation of hyponatremia. The patient had been given a large blood transfusion and had undergone bone marrow transplantation for acute leukemia at 17 years of age, following which he developed chronic hepatitis C virus infection. At the age of 25 years, CBZ (400 mg/day) treatment was begun for temporal lobe epilepsy, and, 1 year later, the CBZ dose was increased to 800 mg/day. At the age of 29 years, the patient developed deep venous thrombosis of the right leg and was treated with catheter-directed thrombolysis using an intravenous catheter filter; he was then placed on warfarin potassium (1.5 mg/day) and bucolome (300 mg/day) orally. On August 11, 2005, the patient was started on interferon-alpha 2b injections (100 μg /week) subcutaneously and ribavirin (800 mg/day) orally for worsening liver function; GOT (glutamic-oxaloacetic transaminase) was 34 IU/l, GPT (glutamic-pyruvic transaminase) was 63 IU/l, and hepatitis C virus-RNA titer was high (700 KIU/ml). Before interferon-alpha and ribavirin therapy were started, blood electrolytes, including serum sodium level, had been consistently normal ([Figure 1](#f1-ijgm-1-21){ref-type="fig"}). The patient was not anemic, and the C-reactive protein level was normal. The patient complained of fatigue 7 days after beginning interferon-alpha 2b and ribavirin therapy; laboratory testing showed that he had hyponatremia ([Figure 1](#f1-ijgm-1-21){ref-type="fig"}).

The patient was 175 cm tall and weighed 71 kg. Temperature was normal (36.2 °C), and the blood pressure (94/58 mmHg) and the pulse rate (80/min) were normal in the recumbent position. Examination of the palpebral conjunctiva indicated anemia. No signs of edema, dehydration, or abnormal pigmentation were present. The patient was fully conscious. Laboratory findings showed anemia and a high C-reactive protein level. Other tests, including interleukin levels, were within normal limits. A plain chest X-ray film was normal. Computed tomography body scans and electrocardiograms were normal. The intensity of the posterior pituitary gland was normal on T1-weighted magnetic resonance imaging.

Despite a hypo-osmotic hyponatremia, the patient's urinary sodium concentration was higher than 20 mEq/l, and urine osmolality was also higher than his blood osmolality ([Table 1](#t1-ijgm-1-21){ref-type="table"}). The serum uric acid was low. Thyroid, adrenal, and renal functions were normal, and plasma renin, aldosterone, and atrial natriuretic peptide (ANP) concentrations were normal ([Table 1](#t1-ijgm-1-21){ref-type="table"}).

The CBZ, warfarin potassium, and bucolome could not be discontinued because they were all essential; in particular, of all the other antiepileptic regimens, only CBZ was effective for treating his epilepsy. Furthermore, the interferon-alpha 2b and ribavirin treatments were considered essential to treat his chronic hepatitis C virus infection for one year.

The arginine vasopressin (AVP) level and the plasma osmolality were normalized to 6.1 pg/ml and 291 mosmol/kg, respectively, by administration of dimethylchlortetracycline (DMC) (900 mg/day) and restriction of water intake (20 ml/kg body weight) ([Figure 1](#f1-ijgm-1-21){ref-type="fig"}). Lithium (400 mg/day) therapy for one year resulted in normonatremia, with a plasma AVP concentration of less than 0.5 pg/ml ([Figure 1](#f1-ijgm-1-21){ref-type="fig"}); this effectively prevented the development of hyponatremia. Administration of lithium with restriction of water intake was discontinued one year later. Subsequently, the hyponatremia worsened during interferon-alpha 2b therapy ([Figure 1](#f1-ijgm-1-21){ref-type="fig"}). Two weeks later, the interferon-alpha 2b therapy was also stopped, and the hyponatremia completely recovered 6 months later while CBZ, warfarin potassium, and bucolome were continued ([Figure 1](#f1-ijgm-1-21){ref-type="fig"}). One year later, the blood sodium and AVP concentrations were 137 mEq/l and 0.7 pg/ml, respectively.

The basal AVP concentration relative to plasma osmolality was below the normal range in healthy subjects ([Figure 1](#f1-ijgm-1-21){ref-type="fig"}), and it was suppressed by 50% with water loading performed 19 days after starting interferon-alpha 2b injections ([Figure 2](#f2-ijgm-1-21){ref-type="fig"}). Plasma ANP levels decreased after water loading ([Figure 2](#f2-ijgm-1-21){ref-type="fig"}). One year after discontinuing interferon-alpha 2b therapy, while still taking CBZ, warfarin potassium, and bucolome, a second water-loading test showed that the minimum plasma sodium and osmolality values obtained 4 hours after water loading were higher than those obtained at the time of the first water-loading test, but they were still lower than those in healthy subjects ([Figure 2](#f2-ijgm-1-21){ref-type="fig"}), and they were accompanied with a nonsuppressive sodium concentration and osmolality in the urine. The cumulative urine volume excretion increased more than during the first water-loading test, but it was still lower than in healthy subjects ([Figure 2](#f2-ijgm-1-21){ref-type="fig"}). The baseline plasma AVP level was higher than it had been during the first water-loading test, and it was not suppressed after water loading, while the plasma ANP levels at baseline and during water loading were normalized ([Figure 2](#f2-ijgm-1-21){ref-type="fig"}).

Discussion
==========

CBZ-induced hyponatremia is uncommon in patients treated with CBZ alone ([@b7-ijgm-1-21]). Although the predisposing risk factors include age, CBZ dosage/level, and polypharmacy, polypharmacy is a particularly important risk factor ([@b13-ijgm-1-21]). The present patient developed hyponatremia after receiving interferon-alpha 2b therapy while on CBZ treatment, and the hyponatremia recovered completely when the interferon-alpha 2b therapy was stopped. The laboratory data indicate that the hyponatremia was not due to adrenal insufficiency, such as Sheehan's syndrome, with interferon treatment ([@b15-ijgm-1-21]), but might have been due to abnormal antidiuresis ([@b22-ijgm-1-21]).

The abnormal antidiuresis was confirmed by the marked decrease in the cumulative urine excretion for 4 hours after water loading. Though it has generally been considered dangerous to perform the water-loading test in patients with hyponatremia, in the present case, no serious adverse events occurred during the water-loading test.

There have been many reports of hyponatremia in patients treated with interferon ([@b9-ijgm-1-21]; [@b1-ijgm-1-21]; [@b14-ijgm-1-21]; [@b2-ijgm-1-21]; [@b3-ijgm-1-21]). However, the mechanism is unclear.

In healthy subjects, plasma ANP concentration increases as plasma volume increases ([@b11-ijgm-1-21]). Although patients with SIAD show various changes ([@b10-ijgm-1-21]; [@b12-ijgm-1-21]), in the present case, SIAD was suppressed by the increase in plasma volume induced by water loading. Therefore, ANP secretion did not cause the SIAD. Another possible cause is a neoplasm ([@b10-ijgm-1-21]). However, in the present patient, there was no evidence of a neoplasm. The patient's high C-reactive protein level may have caused SIAD. Although such hyponatremia may be caused by increased interleukin-1β or -6 levels ([@b16-ijgm-1-21]; [@b4-ijgm-1-21]), blood levels of these cytokines were not elevated in the present patient. Various autoimmune diseases induced by interferon-alpha therapy ([@b5-ijgm-1-21]) may cause SIAD due to the presence of a V2 receptor-stimulating antibody, such as the thyrotropin-stimulating hormone receptor-stimulating antibody found in Grave's disease. Alternately, interferon alpha may cause constitutive activation of the V2 receptor with polymorphism, as shown when a mutation of the V2 receptor causes an SIADH-like clinical picture ([@b6-ijgm-1-21]). The possibilities are unlikely because there are no reports in the literature.

The most likely cause of the hyponatremia in the present case was that interferon therapy may have reinforced a direct or indirect pharmacological effect of other drugs on the renal tubules. To the best of our knowledge, hyponatremia caused by administration of warfarin with bucolome or ribavirin alone has not been reported in the literature. Also, interferon therapy alone has not been demonstrated to cause SIAD. Most patients appear to develop SIAD in combination with other drugs ([@b9-ijgm-1-21]; [@b1-ijgm-1-21]; [@b14-ijgm-1-21]; [@b2-ijgm-1-21]; [@b3-ijgm-1-21]). In fact, CBZ is known to sensitize the renal distal tubules ([@b17-ijgm-1-21]; [@b21-ijgm-1-21]; [@b19-ijgm-1-21]) or to cause inappropriate secretion of AVP ([@b18-ijgm-1-21]), thus, CBZ could have caused the abnormal antidiuresis in the present case. In addition, hyponatremia has been shown to improve following withdrawal of CBZ ([@b8-ijgm-1-21]). However, in the present case, CBZ could not be stopped because it was essential. In addition, the possibility that CBZ causes hyponatremia is supported by the observation that lithium therapy and DMC are useful to treat it ([@b20-ijgm-1-21]), although lithium and CBZ in combination have been reported to be neurotoxic. It should be emphasized that prescribing these medications together should be done with caution. In the present case, CBZ therapy alone did not cause hyponatremia, and the combination of CNZ and interferon therapy may have caused the hyponatremia. This finding supports the hypothesis that interferon-alpha 2b is a predisposing risk factor for CBZ-induced hyponatremia. Although the factors associated with an increased risk for CBZ-induced hyponatremia are less well understood ([@b13-ijgm-1-21]), interferon therapy should be considered a predisposing risk factor. Although CBZ levels were not drawn before and after the introduction of interferon alpha in any of the reported cases, CBZ blood levels would have helped establish CBZ as a predisposing risk factor.

In conclusion, we report the case of a young man who developed SIAD following interferon-alpha 2b therapy for chronic hepatitis C virus. The SIAD may have been caused by sensitizing substances that may have enhanced the direct or indirect pharmacological effects of interferon-alpha on the renal distal tubules. Patients on CBZ therapy should be observed carefully for the development of hyponatremia when they are started on interferon-alpha 2b therapy.
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![Changes in serum sodium (Na) concentration (**•^--^•**) and plasma vasopressin (AVP) concentration (○⋯○) before and during interferon-alpha 2b therapy during water intake restriction with dimethylchlortetracycline (DMC) or lithium, and after their discontinuation. The carbamazepine, warfarin potassium, and bucolome had been administered for more than 2 years before hyponatremia developed and had been continued afterwards. The stippled bar represents the normal serum Na concentration range, and the dotted line represents the lower limit of the normal AVP concentration range.](ijgm-1-21f1){#f1-ijgm-1-21}

![Changes in blood and urine sodium concentrations and osmolality, and in plasma atrial natriuretic hormone (ANP) and vasopressin (AVP) levels, and cumulative urine volume with water loading (20 ml/kg) 19 days after beginning interferon-alpha 2b therapy while continuing carbamazepine, warfarin, and bucolome, (**•^--^•**) and the corresponding changes (○⋯○) during repeated water loading one year after discontinuation of interferon-alpha 2b therapy. Each stippled area represents the normal range.](ijgm-1-21f2){#f2-ijgm-1-21}

###### 

Endocrinological analysis during the week after admission

                                                       **Blood**                                                                  **Urine**
  ---------------------------------------------------- ------------------------- ------------------------------------------------ -------------------------
  Sodium                                               124 mEq/l                                                                  95 mEq/l
  Osmolality                                           260 mosmol/kg                                                              710 mosmol/kg
                                                       Blood                                                                      
  Vasopressin                                          0.4 pg/ml (0.5--3.1)      Renin                                            4.3 pg/ml (2.5--21)
  Aldosterone                                          65 pg/ml (45--106)        ANP                                              40.5 pg/ml (0--43)
  TSH                                                  2.1 μU/ml (0.30--4.30)    Antithyroglobulin antibody                       \<0.3 U/ml (\<0.3)
  Free T~3~                                            2.39 pg/ml (2.00--4.90)   Antiperoxidase antibody                          \<0.1 U/ml (\<0.1)
  Free T~4~                                            0.91 ng/dl (0.70--1.80)   TSH receptor antibody                            \<1.0 IU/l (\<1.0)
  Cortisol[\*](#tfn1-ijgm-1-21){ref-type="table-fn"}   17 μg/dl (4--19)          ACTH[\*](#tfn1-ijgm-1-21){ref-type="table-fn"}   10.5 pg/ml (4.4--48)
  Interleukin-1β                                       \<0.125 pg/ml (\<0.125)   Interleukin-6                                    1.92 pg/ml (0.22--4.62)

**Notes:**

Sampled at 8 AM. ANP; atrial natriuretic hormone.
